These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2897925)

  • 61. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modulation by enkephalin analogues and neuroleptics of apomorphine-induced stereotypy and turning behaviour in rats.
    Polgár K; Máté I; Till M; Székely JI
    Neuropharmacology; 1987 Sep; 26(9):1309-14. PubMed ID: 2890116
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390.
    Barasi S; Ben-Sreti MM; Clatworthy AL; Duggal KN; Gonzalez JP; Robertson J; Rooney KF; Sewell RD
    Br J Pharmacol; 1987 Jan; 90(1):15-22. PubMed ID: 3545350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dopamine receptors mediate drug-induced but not Pavlovian conditioned contralateral rotation in the unilateral 6-OHDA animal model.
    Carey RJ
    Brain Res; 1990 May; 515(1-2):292-8. PubMed ID: 2113414
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SKF 38393 and apomorphine modify locomotion and exploration in rats placed on a holeboard by separate actions at dopamine D-1 and D-2 receptors.
    Fletcher GH; Starr MS
    Eur J Pharmacol; 1985 Nov; 117(3):381-5. PubMed ID: 3878300
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Atypical neuroleptics suppress dopaminergic behavioral supersensitivity.
    Schremmer C; Morgenstern R; Fink H; Ott T
    Psychopharmacology (Berl); 1990; 100(3):399-403. PubMed ID: 1969173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Conditioned behavioural responses to apomorphine: extinction and haloperidol-induced inhibition.
    Welsch-Kunze S; Nowak K; Kuschinsky K
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Dec; 338(6):671-7. PubMed ID: 3244399
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination.
    Palermo-Neto J; Bernardi MM; Saban R
    Pharmacology; 1984; 28(4):203-10. PubMed ID: 6539476
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
    Pierce RC; Rowlett JK; Bardo MT; Rebec GV
    Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions.
    Mailman RB; Schulz DW; Lewis MH; Staples L; Rollema H; Dehaven DL
    Eur J Pharmacol; 1984 May; 101(1-2):159-60. PubMed ID: 6235121
    [No Abstract]   [Full Text] [Related]  

  • 72. Influence of SCH 23390, a DA1-receptor antagonist, on the behavioural responsiveness to small and large doses of apomorphine in rats.
    Cuomo V; Cagiano R; Colonna M; Renna G; Racagni G
    Neuropharmacology; 1986 Nov; 25(11):1297-300. PubMed ID: 2948132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A putative multipartite model of haloperidol interaction in apomorphine-disturbed behavior of the dog.
    Wauquier A; Melis W; Niemegeers CJ; Janssen PA
    Psychopharmacology (Berl); 1978 Dec; 59(3):255-8. PubMed ID: 104328
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced gnawing in sensitized mice.
    Zetler G
    Neuropharmacology; 1985 Mar; 24(3):251-9. PubMed ID: 2859544
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of apomorphine administration on rearing activity of control and experimental rats withdrawn from long-term haloperidol treatment.
    Bernardi MM; Palermo-Neto J
    Gen Pharmacol; 1984; 15(4):363-5. PubMed ID: 6541605
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of dihydroergotoxine on some dopamine-related behaviors in rats.
    Flório JC; Palermo-Neto J
    Gen Pharmacol; 1990; 21(4):411-5. PubMed ID: 2379797
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dopaminergic and cholinergic influences on motor behavior in chickens.
    Sanberg PR
    J Comp Psychol; 1983 Mar; 97(1):59-68. PubMed ID: 6872506
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cyclo (Leu-Gly) + haloperidol: effects on dopamine receptors and conditioned avoidance responding.
    Bean AJ; Elgin RJ; Cooper DM; Martin GE
    Peptides; 1987; 8(1):39-44. PubMed ID: 3575153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.